Measuring Public Preferences for Statin Therapy Using the Smallest Worthwhile Difference

2026/02/16 by Yan Luo, Hiroshi Kawakami, Satoshi Funada +7 · 1 voice
Economics, Econometrics and Finance · Medicine · #Health Systems, Economic Evaluations, Quality of Life #Medication Adherence and Compliance #Pharmaceutical Economics and Policy

paper · doi:10.1001/jamainternmed.2025.7958

openalex publication_date 2026/02/16 · openalex created_date 2026/02/17 · openalex updated_date 2026/07/31

Abstract

This survey study uses the smallest worthwhile difference to assess US and Japanese individuals’ willingness to take statins based on expected risk-reduction benefits and burden.

Citations

• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Discussions

• For primary prevention of stroke and heart attack people often expect more of statins than they get doi.org/10.1001/jama... [bsky, 0 points, 0 comments]

Related

• Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations
• Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease
• Ten-Year Evolution of Statin Eligibility and Use in a Population-Based Cohort
• Cardiovascular risk estimation and statin adherence: a historical cohort study protocol
• The Prevalent New-user Design for Studies With no Active Comparator: The Example of Statins and Cancer